ICM
MED icon

Invenomic Capital Management’s Medifast MED Stock Holding History

Invenomic Capital Management’s Portfolio MED Stock Details MED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-27,675
Closed -$5M – 173
2022
Q2 		$5M Buy
27,675
+11,839
+75% +$2.12M 0.35% 81
2022
Q1 		$2.23M Buy
+15,836
New +$2.99M 0.24% 93

Other funds holding MED

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Invenomic Capital Management's MED Position: Q3 2022 in Review

Invenomic Capital Management sold out of Medifast (MED) in Q3 2022, closing a stake of 27,675 shares — an estimated $5M sold.

Invenomic Capital Management first reported a position in MED in Q1 2022 and held it in 2 quarters. The position peaked at $5M in Q2 2022. 263 funds tracked by Wall St. Rank hold MED as of Q3 2022.

  • Invenomic Capital Management reported no remaining Medifast position as of Q3 2022 after selling out during the quarter.
  • Invenomic Capital Management sold 27,675 Medifast shares in Q3 2022, an estimated $5M.
  • Invenomic Capital Management first reported a position in Medifast in Q1 2022 and held it in 2 quarters.
  • Invenomic Capital Management's Medifast position peaked at $5M in Q2 2022.
  • 263 funds tracked by Wall St. Rank held Medifast as of Q3 2022.

Based on Invenomic Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.